ci 994 and entinostat
ci 994 has been researched along with entinostat in 9 studies
Research
Studies (9)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Besterman, JM; Bonfils, C; Fournel, M; Frechette, S; Lefebvre, S; Leit, SM; Li, Z; Liu, J; Lu, AH; Mallais, TC; Moradei, OM; Paquin, I; Rahil, J; Tessier, PE; Trachy-Bourget, MC; Vaisburg, AF; Wang, J; Yan, TP | 1 |
| Belosay, A; Gediya, LK; Khandelwal, A; Njar, VC; Purushottamachar, P | 1 |
| Bradner, JE; Grachan, ML; Greenberg, EF; Haggarty, SJ; Mazitschek, R; Warnow, T; West, N | 1 |
| Li, Y; Tang, P; Xie, R; Yuan, Q | 1 |
| Cheng, C; He, J; Ullah, S; Yuan, Q; Yun, F | 1 |
| Codd, R; Gotsbacher, MP; Roth, L | 1 |
| Cao, F; Chen, D; de Weerd, S; Dekker, FJ; van der Wouden, PE; Zwinderman, MRH | 1 |
| Coulson, ME; Cowley, SM; Cross, JM; Hodgkinson, JT; Ismail, O; Pytel, WA; Smalley, JP; Trory, JS | 1 |
| Chou, DH; Holson, EB; Lewis, TA; Maglathlin, RL; Schreiber, SL; Tang, AJ; Wagner, BK; Wagner, FF | 1 |
Other Studies
9 other study(ies) available for ci 994 and entinostat
| Article | Year |
|---|---|
Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
Topics: Antineoplastic Agents; Benzamides; Catalytic Domain; Cell Line; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Models, Molecular; NADH, NADPH Oxidoreductases; Structure-Activity Relationship | 2007 |
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Imidazoles; Male; Neoplasms, Experimental; Phenylenediamines; Prostatic Neoplasms; Pyridines; Transplantation, Heterologous; Tretinoin | 2008 |
Chemical phylogenetics of histone deacetylases.
Topics: | 2010 |
Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Molecular Docking Simulation; Molecular Structure; ortho-Aminobenzoates; Structure-Activity Relationship; Thiocarbamates | 2018 |
Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; ortho-Aminobenzoates; Quinazolinones; Structure-Activity Relationship | 2019 |
Immobilized Metal Affinity Chromatography as a Drug Discovery Platform for Metalloenzyme Inhibitors.
Topics: Chromatography, Affinity; Coordination Complexes; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Discovery; Humans; Imino Acids; Metalloproteins; Metals, Heavy; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2020 |
Induced protein degradation of histone deacetylases 3 (HDAC3) by proteolysis targeting chimera (PROTAC).
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Anilides; Animals; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Mice; Phenylenediamines; Proteolysis; RAW 264.7 Cells; Thalidomide; Ubiquitin-Protein Ligases | 2020 |
A 'click' chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras.
Topics: | 2022 |
Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis.
Topics: Animals; Apoptosis; Benzamides; Cytokines; Dose-Response Relationship, Drug; Glucose; Histone Deacetylase Inhibitors; Histone Deacetylases; Insulin; Insulin Secretion; Insulin-Secreting Cells; Phenylenediamines; Pyridines; Rats; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |